Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 354

1.

Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy.

Weber WP, Haug M, Kurzeder C, Bjelic-Radisic V, Koller R, Reitsamer R, Fitzal F, Biazus J, Brenelli F, Urban C, Paulinelli RR, Blohmer JU, Heil J, Hoffmann J, Matrai Z, Catanuto G, Galimberti V, Gentilini O, Barry M, Hadar T, Allweis TM, Olsha O, Cardoso MJ, Gouveia PF, Rubio IT, de Boniface J, Svensjö T, Bucher S, Dubsky P, Farhadi J, Fehr MK, Fulco I, Ganz-Blättler U, Günthert A, Harder Y, Hauser N, Kappos EA, Knauer M, Landin J, Mechera R, Meani F, Montagna G, Ritter M, Saccilotto R, Schwab FD, Steffens D, Tausch C, Zeindler J, Soysal SD, Lohsiriwat V, Kovacs T, Tansley A, Wyld L, Romics L, El-Tamer M, Pusic AL, Sacchini V, Gnant M.

Breast Cancer Res Treat. 2018 Sep 4. doi: 10.1007/s10549-018-4937-1. [Epub ahead of print] Review.

PMID:
30182349
2.

Toward a Consensus on Centralization in Surgery.

Vonlanthen R, Lodge P, Barkun JS, Farges O, Rogiers X, Soreide K, Kehlet H, Reynolds JV, Käser SA, Naredi P, Borel-Rinkes I, Biondo S, Pinto-Marques H, Gnant M, Nafteux P, Ryska M, Bechstein WO, Martel G, Dimick JB, Krawczyk M, Oláh A, Pinna AD, Popescu I, Puolakkainen PA, Sotiropoulos GC, Tukiainen EJ, Petrowsky H, Clavien PA.

Ann Surg. 2018 Aug 30. doi: 10.1097/SLA.0000000000002965. [Epub ahead of print]

PMID:
30169394
3.

TP53 is not a prognostic marker-clinical consequences of a generally disregarded fact.

Braunschmid T, Kührer I, Mittlböck M, Westerhoff M, Kappel-Latif S, Brammen L, Krishnadath KK, Phillips WA, Gnant M, Kandioler D.

Ann N Y Acad Sci. 2018 Aug 15. doi: 10.1111/nyas.13947. [Epub ahead of print]

PMID:
30112858
4.

Circulating Free Methylated Tumor DNA Markers for Sensitive Assessment of Tumor Burden and Early Response Monitoring in Patients Receiving Systemic Chemotherapy for Colorectal Cancer Liver Metastasis.

Bhangu JS, Beer A, Mittlböck M, Tamandl D, Pulverer W, Taghizadeh H, Stremitzer S, Kaczirek K, Gruenberger T, Gnant M, Bergmann M, Mannhalter C, Weinhäusel A, Oehler R, Bachleitner-Hofmann T.

Ann Surg. 2018 Aug 3. doi: 10.1097/SLA.0000000000002901. [Epub ahead of print]

PMID:
30080722
5.

PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma.

Kollmann D, Ignatova D, Jedamzik J, Chang YT, Jomrich G, Baierl A, Kazakov D, Michal M, French LE, Hoetzenecker W, Schatton T, Asari R, Preusser M, Gnant M, Guenova E, Schoppmann SF.

Oncoimmunology. 2018 Mar 13;7(6):e1435226. doi: 10.1080/2162402X.2018.1435226. eCollection 2018.

PMID:
29872575
6.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017 .

Ann Oncol. 2018 May 3. doi: 10.1093/annonc/mdx806. [Epub ahead of print] No abstract available.

PMID:
29733336
7.

Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial.

Fitzal F, Bjelic-Radisic V, Knauer M, Steger G, Hubalek M, Balic M, Singer C, Bartsch R, Schrenk P, Soelkner L, Greil R, Gnant M; ABCSG.

Ann Surg. 2018 Apr 24. doi: 10.1097/SLA.0000000000002771. [Epub ahead of print]

PMID:
29697452
8.

Randomized clinical trial of the effect of a fibrin sealant patch on pancreatic fistula formation after pancreatoduodenectomy.

Schindl M, Függer R, Götzinger P, Längle F, Zitt M, Stättner S, Kornprat P, Sahora K, Hlauschek D, Gnant M; Austrian Breast and Colorectal Cancer Study Group.

Br J Surg. 2018 Jun;105(7):811-819. doi: 10.1002/bjs.10840. Epub 2018 Apr 17.

9.

Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial.

Zeidan YH, Habib JG, Ameye L, Paesmans M, de Azambuja E, Gelber RD, Campbell I, Nordenskjöld B, Gutiérez J, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Joseph DJ, Crown J, Piccart-Gebhart M, Francis PA.

Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):316-324. doi: 10.1016/j.ijrobp.2018.01.105. Epub 2018 Feb 6.

PMID:
29534902
10.

Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.

Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart MJ, Dowsett M; TransHERA investigators.

Clin Cancer Res. 2018 Jul 1;24(13):3079-3086. doi: 10.1158/1078-0432.CCR-17-3473. Epub 2018 Mar 12.

PMID:
29530933
11.

Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer.

Strobl S, Wimmer K, Exner R, Devyatko Y, Bolliger M, Fitzal F, Gnant M.

Curr Treat Options Oncol. 2018 Mar 12;19(4):18. doi: 10.1007/s11864-018-0535-z. Review.

PMID:
29527635
12.

High Accumulation of Metformin in Colonic Tissue of Subjects With Diabetes or the Metabolic Syndrome.

Paleari L, Burhenne J, Weiss J, Foersch S, Roth W, Parodi A, Gnant M, Bachleitner-Hofmann T, Scherer D, Ulrich CM, Stabuc B, Puntoni M, Coccia G, Petrera M, Haefeli WE, DeCensi A.

Gastroenterology. 2018 Apr;154(5):1543-1545. doi: 10.1053/j.gastro.2017.12.040. Epub 2018 Mar 8. No abstract available.

13.

Optimal duration of adjuvant endocrine therapy: how to apply the newest data.

Wimmer K, Strobl S, Bolliger M, Devyatko Y, Korkmaz B, Exner R, Fitzal F, Gnant M.

Ther Adv Med Oncol. 2017 Nov;9(11):679-692. doi: 10.1177/1758834017732966. Epub 2017 Oct 27. Review.

14.

Explained variation in shared frailty models.

Gleiss A, Gnant M, Schemper M.

Stat Med. 2018 Apr 30;37(9):1482-1490. doi: 10.1002/sim.7592. Epub 2017 Dec 28. No abstract available.

PMID:
29282754
15.

A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients.

Piringer G, Fridrik M, Fridrik A, Leiherer A, Zabernigg A, Greil R, Eisterer W, Tschmelitsch J, Lang A, Frantal S, Burgstaller S, Gnant M, Thaler J; Austrian Breast and Colorectal Cancer Study Group (ABCSG).

Support Care Cancer. 2018 Apr;26(4):1345-1352. doi: 10.1007/s00520-017-3961-8. Epub 2017 Nov 22.

PMID:
29168033
16.

Sized Influences Nodal Status in Women Aged #70 with Endocrine Responsive Breast Cancer.

Fitzal F, Helfgott R, Moinfar F, Gnant M.

Ann Surg Oncol. 2017 Dec;24(Suppl 3):555-556. doi: 10.1245/s10434-017-6156-0. Epub 2017 Nov 20. No abstract available.

PMID:
29159741
17.

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group.

Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13.

PMID:
29146401
18.

Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.

Dubsky P, Curigliano G, Burstein HJ, Winer EP, Gnant M, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.

Ann Oncol. 2018 Jan 1;29(1):281-282. doi: 10.1093/annonc/mdx543. No abstract available.

PMID:
29045519
19.

Inflammatory response and oxidative stress during liver resection.

Schwarz C, Fitschek F, Bar-Or D, Klaus DA, Tudor B, Fleischmann E, Roth G, Tamandl D, Wekerle T, Gnant M, Bodingbauer M, Kaczirek K.

PLoS One. 2017 Oct 18;12(10):e0185685. doi: 10.1371/journal.pone.0185685. eCollection 2017.

20.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Y Brucker S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.

Ann Oncol. 2017 Aug 1;28(8):1700-1712. doi: 10.1093/annonc/mdx308.

PMID:
28838210
21.

Therapeutic Bone-Modifying Agents in the Nonmetastatic Breast Cancer Setting: The Controversy and a Value Assessment.

Gnant M, Van Poznak C, Schnipper L.

Am Soc Clin Oncol Educ Book. 2017;37:116-122. doi: 10.14694/EDBK_177357. Review.

22.

St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment.

Gnant M, Harbeck N, Thomssen C.

Breast Care (Basel). 2017 May;12(2):102-107. doi: 10.1159/000475698. Epub 2017 Apr 26. Review.

23.

Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.

Eisterer W, Piringer G, DE Vries A, Öfner D, Greil R, Tschmelitsch J, Samonigg H, Sölkner L, Gnant M, Thaler J; Austrian Breast and Colorectal Cancer Study Group.

Anticancer Res. 2017 May;37(5):2683-2691.

PMID:
28476845
24.

Objective breast symmetry analysis with the breast analyzing tool (BAT): improved tool for clinical trials.

Krois W, Romar AK, Wild T, Dubsky P, Exner R, Panhofer P, Jakesz R, Gnant M, Fitzal F.

Breast Cancer Res Treat. 2017 Jul;164(2):421-427. doi: 10.1007/s10549-017-4255-z. Epub 2017 May 2.

25.

Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.

Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, Zillikens MC, Glüer CC, de Villiers T, Baber R, Roodman GD, Cooper C, Langdahl B, Palacios S, Kanis J, Al-Daghri N, Nogues X, Eriksen EF, Kurth A, Rizzoli R, Coleman RE.

J Bone Oncol. 2017 Mar 23;7:1-12. doi: 10.1016/j.jbo.2017.03.001. eCollection 2017 Jun. Review.

26.

Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.

Gingras I, Holmes E, De Azambuja E, Nguyen DH, Izquierdo M, Anne Zujewski J, Inbar M, Naume B, Tomasello G, Gralow JR, Wolff AC, Harris L, Gnant M, Moreno-Aspitia A, Piccart MJ, Azim HA Jr.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djw331.

PMID:
28376188
27.

Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.

Singer CF, Tan YY, Fitzal F, Steger GG, Egle D, Reiner A, Rudas M, Moinfar F, Gruber C, Petru E, Bartsch R, Tendl KA, Fuchs D, Seifert M, Exner R, Balic M, Bago-Horvath Z, Filipits M, Gnant M; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2017 Jul 15;23(14):3676-3683. doi: 10.1158/1078-0432.CCR-16-2373. Epub 2017 Jan 31.

28.

Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial.

Smith I, Yardley D, Burris H, De Boer R, Amadori D, McIntyre K, Ejlertsen B, Gnant M, Jonat W, Pritchard KI, Dowsett M, Hart L, Poggio S, Comarella L, Salomon H, Wamil B, O'Shaughnessy J.

J Clin Oncol. 2017 Apr 1;35(10):1041-1048. doi: 10.1200/JCO.2016.69.2871. Epub 2017 Jan 23.

PMID:
28113032
29.

Breast cancer.

Harbeck N, Gnant M.

Lancet. 2017 Mar 18;389(10074):1134-1150. doi: 10.1016/S0140-6736(16)31891-8. Epub 2016 Nov 17. Review.

PMID:
27865536
30.

Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.

Foukakis T, von Minckwitz G, Bengtsson NO, Brandberg Y, Wallberg B, Fornander T, Mlineritsch B, Schmatloch S, Singer CF, Steger G, Egle D, Karlsson E, Carlsson L, Loibl S, Untch M, Hellström M, Johansson H, Anderson H, Malmström P, Gnant M, Greil R, Möbus V, Bergh J; Swedish Breast Cancer Group (SweBCG), the German Breast Group (GBG), and the Austrian Breast & Colorectal Cancer Study Group (ABCSG).

JAMA. 2016 Nov 8;316(18):1888-1896. doi: 10.1001/jama.2016.15865.

PMID:
27825007
31.

Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.

Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Voi M, Gnant M, Hortobagyi G, Baselga J, Moynahan ME.

JAMA Oncol. 2016 Oct 1;2(10):1310-1315. doi: 10.1001/jamaoncol.2016.1279.

32.

Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy.

Exner R, Sachet M, Arnold T, Zinn-Zinnenburg M, Michlmayr A, Dubsky P, Bartsch R, Steger G, Gnant M, Bergmann M, Bachleitner-Hofmann T, Oehler R.

Cancer Med. 2016 Sep;5(9):2350-8. doi: 10.1002/cam4.827. Epub 2016 Jul 25.

33.

Pathological complete remission and long-term outcome-what do we know in 2016?

Gnant M, Steger GG, Bartsch R.

Lancet Oncol. 2016 Jun;17(6):693-694. doi: 10.1016/S1470-2045(16)30038-9. Epub 2016 May 11. No abstract available.

PMID:
27179401
34.

Prognostic impact of breast cancer subtypes in elderly patients.

Bergen ES, Tichy C, Berghoff AS, Rudas M, Dubsky P, Bago-Horvath Z, Mader RM, Exner R, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.

Breast Cancer Res Treat. 2016 May;157(1):91-9. doi: 10.1007/s10549-016-3787-y. Epub 2016 Apr 23.

35.

Editorial comment on 'Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials'.

Gnant M.

Eur J Cancer. 2016 May;59:125-127. doi: 10.1016/j.ejca.2016.02.009. Epub 2016 Mar 28. No abstract available.

PMID:
27033259
36.

A Cross-Sectional Study of Patients' Satisfaction With Totally Implanted Access Ports.

Minichsdorfer C, Füreder T, Mähr B, Berghoff AS, Heynar H, Dressler A, Gnant M, Zielinski C, Bartsch R.

Clin J Oncol Nurs. 2016 Apr;20(2):175-80. doi: 10.1188/16.CJON.175-180.

PMID:
26991711
37.

Breast Cancer Is Our Global Responsibility.

Harbeck N, Gnant M, Thomssen C.

Breast Care (Basel). 2015 Dec;10(6):360. doi: 10.1159/000443159. Epub 2015 Dec 16. No abstract available.

38.

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, Silovski T, Gokmen E, von Minckwitz G, Ejlertsen B, Chia SK, Mansi J, Barrios CH, Gnant M, Buyse M, Gore I, Smith J 2nd, Harker G, Masuda N, Petrakova K, Zotano AG, Iannotti N, Rodriguez G, Tassone P, Wong A, Bryce R, Ye Y, Yao B, Martin M; ExteNET Study Group.

Lancet Oncol. 2016 Mar;17(3):367-77. doi: 10.1016/S1470-2045(15)00551-3. Epub 2016 Feb 10.

PMID:
26874901
39.

Denosumab and fracture risk in women with breast cancer - Author's reply.

Gnant M; all ABCSG-18 investigators.

Lancet. 2015 Nov 21;386(10008):2057-2058. doi: 10.1016/S0140-6736(15)00975-7. Epub 2015 Nov 20. No abstract available.

PMID:
26700393
40.

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.

Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body JJ, Markopoulos C, Santini D, Diel I, Di Leo A, Cameron D, Dodwell D, Smith I, Gnant M, Gray R, Harbeck N, Thurlimann B, Untch M, Cortes J, Martin M, Albert US, Conte PF, Ejlertsen B, Bergh J, Kaufmann M, Holen I.

Ann Oncol. 2016 Mar;27(3):379-90. doi: 10.1093/annonc/mdv617. Epub 2015 Dec 17. Review.

PMID:
26681681
41.

Palbociclib for the treatment of postmenopausal breast cancer - an update.

Steger GG, Gnant M, Bartsch R.

Expert Opin Pharmacother. 2016;17(2):255-63. doi: 10.1517/14656566.2016.1133590. Epub 2016 Jan 14. Review.

PMID:
26679057
42.

St.Gallen-2015 in Vienna: News from a successful breast cancer conference transposition!

Senn HJ, Thürlimann B, Gnant M.

Breast. 2015 Nov;24 Suppl 2:S1. doi: 10.1016/j.breast.2015.07.030. Epub 2015 Oct 4. No abstract available.

PMID:
26439287
43.

TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients.

Kandioler D, Mittlböck M, Kappel S, Puhalla H, Herbst F, Langner C, Wolf B, Tschmelitsch J, Schippinger W, Steger G, Hofbauer F, Samonigg H, Gnant M, Teleky B, Kührer I; p53 Research Group and the Austrian Breast and Colorectal Study Group (ABCSG).

EBioMedicine. 2015 Jun 8;2(8):825-30. doi: 10.1016/j.ebiom.2015.06.003. eCollection 2015 Aug.

44.

Adjuvant Bisphosphonates and Breast Cancer Survival.

Strobl S, Korkmaz B, Devyatko Y, Schuetz M, Exner R, Dubsky PC, Jakesz R, Gnant M.

Annu Rev Med. 2016;67:1-10. doi: 10.1146/annurev-med-053014-103600. Epub 2015 Aug 28. Review.

PMID:
26332000
45.

Activity of T-DM1 in Her2-positive breast cancer brain metastases.

Bartsch R, Berghoff AS, Vogl U, Rudas M, Bergen E, Dubsky P, Dieckmann K, Pinker K, Bago-Horvath Z, Galid A, Oehler L, Zielinski CC, Gnant M, Steger GG, Preusser M.

Clin Exp Metastasis. 2015 Oct;32(7):729-37. doi: 10.1007/s10585-015-9740-3. Epub 2015 Aug 25.

PMID:
26303828
46.

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.

Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, Liu S, Leung S, Geiss G, Snider J, Vickery T, Davies SR, Mardis ER, Gnant M, Sestak I, Ellis MJ, Perou CM, Bernard PS, Parker JS.

BMC Med Genomics. 2015 Aug 22;8:54. doi: 10.1186/s12920-015-0129-6.

47.

Bevacizumab: no comeback in early breast cancer?

Bartsch R, Gnant M, Steger GG.

Lancet Oncol. 2015 Sep;16(9):1001-1003. doi: 10.1016/S1470-2045(15)00124-2. Epub 2015 Aug 10. No abstract available.

PMID:
26272771
48.

Targeting bone microenvironment: Clinical implications.

Gnant M.

Breast. 2015 Nov;24 Suppl 2:S49-50. doi: 10.1016/j.breast.2015.07.012. Epub 2015 Aug 1. No abstract available.

PMID:
26238438
49.

St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion.

Gnant M, Thomssen C, Harbeck N.

Breast Care (Basel). 2015 Apr;10(2):124-30. doi: 10.1159/000430488. Review.

50.

Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.

Promberger R, Dubsky P, Mittlböck M, Ott J, Singer C, Seemann R, Exner R, Panhofer P, Steger G, Bergen E, Gnant M, Jakesz R, Bago-Horvath Z, Rudas M, Bartsch R.

Clin Breast Cancer. 2015 Dec;15(6):505-11. doi: 10.1016/j.clbc.2015.06.007. Epub 2015 Jun 18.

PMID:
26195436

Supplemental Content

Support Center